Clinical significance of organ‐ and non‐organ‐specific autoantibodies on the response to anti‐viral treatment of patients with chronic hepatitis C

Gatselis, Nikolaos; Georgiadou, Sarah P.; Koukoulis, George Κ.; Tassopoulos, Nicholas C.; Zachou, Kalliopi; Liaskos, Christos; Hatzakis, Angelos; Dalekos, Georgios N.

doi:10.1111/j.1365-2036.2006.03165.x

Cited by 35 publications

(24 citation statements)

References 53 publications

(190 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The histologic evaluation for inflammation and fibrosis was assessed using the Knodell histologic activity index [28] . According to previous publications of our group [29][30][31] , for statistical reasons the patients were divided into two groups: (1) according to inflammation: minimal/mild (score 0-8) and moderate/severe (score 9-18); and (2) according to fibrosis: none/mild (score 0-1) and moderate/severe/cirrhosis (score 2-3).…”

Section: Patientsmentioning

confidence: 99%

Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma

Norman¹

2015

WJH

View full text Add to dashboard Cite

AIM:To assess serum cartilage oligomeric matrix protein (COMP) as a marker of cirrhosis and risk of progression to hepatocellular carcinoma (HCC). METHODS: A COMP enzyme-linked immunosorbent ORIGINAL ARTICLEassay was used to test 187 patients with chronic liver diseases at the time point of first evaluation. The selected patients included 72 with chronic hepatitis B infection, 75 with chronic hepatitis C infection, 22 with primary biliary cirrhosis, 7 with autoimmune hepatitis type 1, and 11 with alcoholic liver disease. Demographic, biochemical, histological and clinical characteristics of the patients were recorded at the first evaluation. One hundred and forty-seven patients were followed for a median [interquartile range (IQR)] duration of 96.5 (102) mo. The clinical, biochemical and histological data, as well as the development of cirrhosis, HCC according to internationally accepted criteria and in case of death, a liver-related cause during the follow-up period, were recorded at the electronic database of our clinic. COMP determination was also performed in 43 healthy individuals who served as the control study group. RESULTS:COMP positivity (> 15 U/L) was detected in 22%-36% among chronic liver disease groups. Strikingly, almost 83% of COMP-positive patients were cirrhotic at baseline, independently of cause of liver disease. Among the patients who developed HCC during follow-up, 73.7% (14/19) were COMP positive at baseline. COMP positivity was significantly associated with older age (P < 0.001), advanced fibrosis (P = 0.001) and necroinflammatory activity (P = 0.001), higher aspartate aminotransferase (P < 0.001), alanine aminotransferase (P < 0.02), γ-glutamyl transpeptidase (P = 0.003), alkaline phosphatase (P = 0.001), bilirubin (P < 0.05), international normalized ratio (P = 0.002) and alpha-fetoprotein levels (P < 0.02), and lower albumin (P < 0.001), and platelet count (P = 0.008). COMP levels [median (IQR)] were significantly higher in cirrhotics compared to non-cirrhotics [13.8 (7.9) U/L vs 9.8 (4.6) U/L, respectively; P < 0.001]. On multivariate logistic regression analysis, COMP-positivity was independently associated only with cirrhosis (OR = 4.40, 95%CI: 1.33-14.69, P = 0.015). Kaplan-Meier analysis showed that COMP positivity was significantly associated with HCC development (P = 0.007) and higher incidence of liver-related death (P < 0.001).CONCLUSION: Elevated COMP levels are strongly associated with cirrhosis and HCC progression. Serum COMP is a new promising non-invasive biomarker for HCC risk assessment in surveillance programs.

show abstract

Section: Patientsmentioning

confidence: 99%

Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma

Norman¹

2015

WJH

View full text Add to dashboard Cite

show abstract

“…Circulating autoantibodies, including antinuclear antibodies (ANA), RF, antiphospholipid (aPL) antibodies, cryoglobulins, anti-smooth muscle actin (SMA) antibodies, liver-kidney microsomal antibodies (LKM), and antithyroid peroxidase, are often detected in patients with chronic HCV infection [3,74,75]. ANA, RF and SMA are the most common.…”

Section: Autoantibodies Associated With Chronic Hcv Infectionmentioning

confidence: 99%

“…Gatselis et al [74] found a negative correlation between the efficacy of antiviral treatment for HCV and the presence of ANA and SMA before treatment and their increase during therapy. A highly favourable treatment response was associated with an absence of ANA and a decrease in SMA titres during therapy.…”

Section: Autoantibodies Associated With Chronic Hcv Infectionmentioning

confidence: 99%

Hepatitis C virus and autoimmunity

Böckle

Sepp

2010

Autoimmun Highlights

View full text Add to dashboard Cite

Hepatitis C virus infection is associated with several extrahepatic manifestations. About 60% of patients infected with HCV develop at least one extrahepatic manifestation. The majority of these diseases seem to be triggered through autoimmune mechanisms, such as autoantibody production, autoreactive T cells and complex autoimmune mechanisms leading to systemic autoimmune disorders. In this review we categorize these diseases into three groups according to the main pathogenetic process involved, in particular B-cell-mediated, T-cell-mediated and complex autoimmune systemic diseases.

show abstract

“…Hierzu gehört das Auftreten von Autoantikörpern, welche durch Aktivierung von B-Lymphozyten durch das Virus entstehen und zu vaskulitischen Krankheitsbildern mit pulmonaler Hämorrha-gie und Glomerulonephritis führen kön-nen [10]. In einer Reihe von Studien ist die Prävalenz von Autoantikörpern -am häufigsten die von Rheumafaktoren, antinukleären Antikörpern (ANA), antimitochondrialen Antikörpern (AMA), Antikörpern gegen glatte Muskulatur (AS-MA), Liver-Kidney-Microsomes-Antikörpern (LKM) und Schilddrüsenanti-körpern -bei Patienten mit chronischer Hepatitis-C-Infektion untersucht worden [2,7,11] [4,10]. Insgesamt bleibt die klinische Relevanz der bei Patienten mit Hepatitis C nachgewiesenen Autoantikör-per aber häufig unklar und geht in vielen Fällen nicht mit einer entsprechenden klinischen Manifestation einher.…”

Section: Hepatitis C Und Autoimmunitätunclassified

Hämoptysen und akutes Nierenversagen bei einem 29-jährigen Patienten mit chronischer Hepatitis C

et al. 2008

View full text Add to dashboard Cite

A 29-year-old male patient with chronic hepatitis C infection and interferon alpha therapy in his medical history was admitted to the hospital because of the clinical manifestation of a pulmonary renal syndrome. High titers of proteinase-3-ANCA were detected, while an infectious agent was ruled out. After diagnosis of Wegener's granulomatosis the patient received prednisolone and cyclophosphamide pulse therapy and remission developed rapidly. Chronic hepatitis C infection as well as interferon therapy are frequently associated with autoimmune disorders. We assume that the interferon therapy itself has triggered autoimmune processes resulting in Wegener's granulomatosis in our patient. Thus we recommend to search specifically for autoimmune disorders in the past medical history and if necessary to consider a screening for autoantibodies before starting an interferon therapy. An autoimmune disease should also be taken into account if new symptoms develop under an ongoing interferon alpha therapy.

show abstract

Clinical significance of organ‐ and non‐organ‐specific autoantibodies on the response to anti‐viral treatment of patients with chronic hepatitis C

Abstract: SUMMARY BackgroundDevelopment of organ-and non-organ-specific autoantibodies has been reported in hepatitis C virus patients treated with interferon-a plus/minus ribavirin.

Cited by 35 publications

References 53 publications

Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma

Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma

Hepatitis C virus and autoimmunity

Hämoptysen und akutes Nierenversagen bei einem 29-jährigen Patienten mit chronischer Hepatitis C

Contact Info

Product

Resources

About